Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆
Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426068936?dgcid=rss_sd_all
Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426068936?dgcid=rss_sd_all
“Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆.” Annals of Oncology.
@article{article36224,
title = {Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426068936?dgcid=rss_sd_all}
}